Research Leadership GSK has experienced recent leadership changes in its R&D and CFO functions, signaling potential shifts in priorities and budgeting for strategic initiatives. This presents an opening to engage on long-term partnerships aligned with evolving research programs and financial planning.

Clinical Pipeline Active development of risvutatug rezetecan, a B7-H3-targeted antibody-drug conjugate with positive Phase III outcomes in relapsed small-cell lung cancer, indicates continued demand for advanced biopharma services, data analytics, and regulatory support.

Tech Modernization GSK’s tech stack includes cloud, analytics, and design tools (AWS CloudFormation, Sigma Computing, UXPin, Workspace One, Delphi). Opportunities exist to offer integrated cloud optimization, data warehousing, security, and UX-enabled digital health solutions.

Strategic Talent Upcoming governance changes with an independent non-executive director and exits in key roles may drive initiatives in risk management, governance tooling, and leadership onboarding services, including training and change management.

Infrastructure Footprint Historical asset divestitures such as the 2017 data center sale suggest a leaner IT footprint with potential needs for modernized data center migrations, colocation, or cloud-native resilience solutions to support ongoing operations.